Staff Reporter :
The Directorate General of Drug Administration (DGDA) suspended production, sale, distribution and export all types of Ranitidine like medicines by issuing a public notice on Thursday.
Sources said, the decision has been taken as cancer-causing ingredients have been found in its raw materials.
Major General Md. Mahbubur Rahman, the Director General of DGDA signed the public notice in which it had been said that the raw materials and finished products of Ranitidine were not acceptable for human health. In the notice it has been said that the level of NDMA Impurity in the finished medicine and in Ranitidine Hydrochloride, the raw materials of the medicine, imported from India’s M/S Saraka Laboratories and M/S Life science are found more than the acceptable level.
So the medicines are suspended, it added.
The ranitidine group’s tablets were using to stop producing gas in human liver which generally known as gastric problem.
The samples of the medicine and its raw materials are examined in World Health Organisation accredited laboratories under the supervision of DGDA recently.
Earlier on September 29, DGDA decided to stop producing and selling of all types of Ranitidine tablets after a meeting held in its building in Mohakhali in the capital with the leaders of drug industries owners’ organization.
